US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Garcia, Winker go deep as Nats end slide, beat struggling Twins 12
WASHINGTON (AP) — Luis García Jr. homered and drove in three runs, Eddie Rosario also had three RBIs2024-05-22- If you had offered David Moyes a draw at kick-off, he would most certainly have taken it. If you had2024-05-22
The Golden Bachelor couple Gerry Turner and Theresa Nist are getting a divorce
J. Lo invests $20 million on documentary, possible new "Bachelor" spinoff 02:442024-05-22Jeffrey Dean Morgan cuddles up to Hilarie Burton as loved
Jeffrey Dean Morgan cuddled up to Hilarie Burton as the loved-up couple led the stars at the AMC Net2024-05-22Midwest storms: Large hail, torrential rain and tornadoes and more is coming
OMAHA, Neb. (AP) — Residents in Omaha, Nebraska, awoke to weather sirens blaring and widespread powe2024-05-22ULTIMATE GRAND NATIONAL GUIDE: Mail Sport's expert gives his verdict on all 34 runners
The £1million Randox Grand National is the biggest race of the British jumps season and one of the m2024-05-22
atest comment